A sheet structure formed from an extracellular matrix (ECM) composition that includes acellular ECM derived from small intestine submucosa (SIS) tissue, gentamicin and vancomycin. The sheet structure is configured to modulate inflammation of damaged biological tissue and induce cell and tissue proliferation, bioremodeling of the damaged biological tissue, and regeneration of new tissue and tissue structures with site-specific structural and functional properties, when the tissue structure is delivered to the damaged biological tissue.

An antithrombogenic metallic material includes a metallic material whose surface is coated with a coating material, the coating material containing: a phosphonic acid derivative or a catechol derivative; a polymer containing, as a constituent monomer, a compound selected from the group consisting of alkyleneimines, vinylamines, allylamines, lysine, protamine, and diallyldimethylammonium chloride; and an anionic compound containing a sulfur atom and having anticoagulant activity; the polymer being covalently bound to the phosphonic acid derivative or the catechol derivative, the phosphonic acid derivative or the catechol derivative being bound to the metallic material through a phosphonic acid group or a catechol group thereof, wherein the abundance ratio of nitrogen atoms to the abundance of total atoms as measured by X-ray photoelectron spectroscopy (XPS) on the surface is 4.0 to 13.0 atomic percent.

Disclosed are an absorbable iron-based alloy implanted medical device (1) and preparation method thereof. The device (1) comprises an iron-based alloy base (11), a degradable polymer (13) arranged on the surface of the iron-based alloy base, and an alkaline protector (12) arranged on the surface of the iron-based alloy base. The alkaline protector (12) contains at least one alkaline substance capable of neutralizing the acidic substance produced by the polymer at the early stage after the device is implanted to delay the corrosion of the iron-based alloy base (1) in the early stage of implantation, hence the iron-based alloy base (12) would not substantially corrode or would corrode slowly, clinically satisfying the mechanical properties and requirements of the device (1) in the early stage of implantation; and in the meantime, after the neutralization and consumption of the alkaline protector (12) exposes the base (11), the base (11) can still accelerate the corrosion speed thereof in the acidic environment formed by the polymer (13), so as to clinically satisfy the requirement of the corrosion cycle of the device (1) at the same time.

Methods for inhibiting stenosis, obstruction and/or calcification of a heart valve following implantation in a vessel having a wall are disclosed. In one aspect the method includes providing a bioprosthetic heart valve mounted on an elastical stent; treating the bioprosthetic heart valve with a tissue fixative; coating the stent and the bioprosthetic valve with a coating composition including one or more therapeutic agents; implanting the bioprosthetic valve into the vessel in a diseased natural valve site; eluting the coating composition from the bioprosthetic valve; and inhibiting stenosis, obstruction and/or calcification of the bioprosthetic heart valve by preventing the attachment of stem cells to the bioprosthetic heart valve, the stem cells circulating external and proximate to the bioprosthetic heart valve by activating nitric oxide production (i) in the circulating stem cells, (ii) in an endothelial cell lining covering the bioprosthetic heart valve tissue, (iii) or both.

Crosslinked polymer coatings which provide the lubrication of the inner surface of a cartridge used as an intermediary for the implantation of intraocular lenses (IOL) in order to replace the natural lens with an artificial lens after removal of the natural lens that has lost its transparency in cataract surgery, in order to facilitate the delivery of the intraocular lens are provided. The objective of the invention is to develop a coating which will enable the intraocular lens (IOL) to be easily implanted through the cartridge without damaging it, remains stable during its long shelf life, and is flexible and lubricious.

This invention relates to a method for hiding stains in medical dressings and other textile substrates. The method includes applying a metallic silver coating to a textile substrate via a plasma enhanced chemical vapor deposition (PECVP) process. The metallic silver coating effectively hides any stain that comes into direct contact with the treated substrate by transferring the liquid beneath the surface of the coating. The invention also relates to textile substrates containing metallic silver coatings.

Disclosed herein are compounds of the formula: A-L-R.sub.1(I), wherein the these variables are defined herein, as well as medical devices comprising said compounds. The present disclosure also provides pharmaceutical compositions comprising the compounds or medical devices disclosed herein. Further, the present disclosure provides methods of treatment using the compounds, medical devices, or pharmaceutical compositions disclosed herein.

A CO.sub.2 processed sheet structure comprising ECM derived from mammalian submucosa tissue, which can be formed into a pouch configured to encase a medical device.

Methods for inhibiting stenosis, obstruction and/or calcification of a heart valve following implantation in a vessel having a wall are disclosed. In one aspect the method includes providing a bioprosthetic heart valve mounted on an elastical stent; treating the bioprosthetic heart valve with a tissue fixative; coating the stent and the bioprosthetic valve with a coating composition including one or more therapeutic agents; implanting the bioprosthetic valve into the vessel in a diseased natural valve site; eluting the coating composition from the bioprosthetic valve; and inhibiting stenosis, obstruction and/or calcification of the bioprosthetic heart valve by preventing the attachment of stem cells to the bioprosthetic heart valve, the stem cells circulating external and proximate to the bioprosthetic heart valve by activating nitric oxide production (i) in the circulating stem cells, (ii) in an endothelial cell lining covering the bioprosthetic heart valve tissue, (iii) or both.

Bioprosthetic tissues are treated by immersing or otherwise contacting fixed, unfixed or partially fixed tissue with a glutaraldehyde solution that has previously been heat-treated or pH adjusted prior to its contact with the tissue. The prior heat treating or pH adjustment of the glutaraldehyde solution causes its free aldehyde concentration to decrease by about 25% or more, preferably by as much as 50%, and allows a stabilized glutaraldehyde solution to be obtained at the desired concentration and pH for an optimal fixation of the tissue at high or low temperature. This treatment results in a decrease in the tissue's propensity to calcify after being implanted within the body of a human or animal patient.